Parkinson’s disease clinical research in 7MM focuses on disease-modifying agents
Treatments targeting alpha-synuclein aggregation account for 26% of the 7MM pipeline of disease-modifying therapies for Parkinson's.
Treatments targeting alpha-synuclein aggregation account for 26% of the 7MM pipeline of disease-modifying therapies for Parkinson's.